Grant: Research Tools and Instruments
Simon Fraser University
$150,000.00
An Automated Synthesis Platform to Support Drug Discovery and Reaction Development
EF 2016-17
Résumé
Rapid parallel synthesis, especially in conjunction with screening of chemical fragments (fragment-based drug discovery), is a mainstay of modern medicinal chemistry and allows for rapid production of multiple analogs of a lead or hit structure, in parallel reactions. A single chemist, utilizing validated fragments or intermediates and the automated synthesis platform requested in this RTI application, can prepare dozens or even hundreds of compounds in a matter of days, greatly accelerating the hit-to-lead process. In addition, this technology is ideally suited for the rapid and reproducible optimization of many parameters that are critical to both reaction discovery and development. The research described in this proposal will take advantage of both of these unique capabilities through the discovery and optimization of biologically active small molecules as drug leads or monomers to be used in polymer synthesis, and parallel screening of reaction conditions for optimization purposes. Importantly, these efforts will complement our existing strengths in high-throughput screening in the Center for High-Throughput Chemical Biology located in the Faculty of Science at SFU by creating new opportunities for the synthesis of structurally diverse chemical libraries, rapid lead optimization and natural product diversification. Presently, we only have the capacity to make small compound collections one-at-a-time using standard laboratory equipment, which has significantly limited our ability to capitalize on new discoveries of lead candidates, validated therapeutic targets, and new polymeric materials. The requested equipment would allow HQP to synthesize, in parallel, libraries of up to 96 compounds at a time, perform reaction work up, and crude purifications with minimal user input. There is no similar or related equipment at SFU, and a further delay in acquiring the automated synthesis platform would significantly impact our ability to translate expertise in chemical screening and synthesis into practical advances in medicine and materials.
Programme
Research Tools and Instruments
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
RTI-2017-00201
Name nom
Britton, Robert
Department département
Chemistry - Chemistry
Organization id
5
Institution établissement
Simon Fraser University
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2017
Award amount
150000
Program id
RTI
Program name en
Research Tools and Instruments
Program name fr
Outils et instruments de recherche
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1604
Committee name en
Chemistry (RTI)
Committee name fr
Chimie (OIR)
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3703
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic syntheses
Research subject fr
Synthèses organiques
Partie
1
Nb partie
1
Application title
An Automated Synthesis Platform to Support Drug Discovery and Reaction Development
Keyword
NSERC
Application summary
Rapid parallel synthesis, especially in conjunction with screening of chemical fragments (fragment-based drug discovery), is a mainstay of modern medicinal chemistry and allows for rapid production of multiple analogs of a lead or hit structure, in parallel reactions. A single chemist, utilizing validated fragments or intermediates and the automated synthesis platform requested in this RTI application, can prepare dozens or even hundreds of compounds in a matter of days, greatly accelerating the hit-to-lead process. In addition, this technology is ideally suited for the rapid and reproducible optimization of many parameters that are critical to both reaction discovery and development. The research described in this proposal will take advantage of both of these unique capabilities through the discovery and optimization of biologically active small molecules as drug leads or monomers to be used in polymer synthesis, and parallel screening of reaction conditions for optimization purposes. Importantly, these efforts will complement our existing strengths in high-throughput screening in the Center for High-Throughput Chemical Biology located in the Faculty of Science at SFU by creating new opportunities for the synthesis of structurally diverse chemical libraries, rapid lead optimization and natural product diversification. Presently, we only have the capacity to make small compound collections one-at-a-time using standard laboratory equipment, which has significantly limited our ability to capitalize on new discoveries of lead candidates, validated therapeutic targets, and new polymeric materials. The requested equipment would allow HQP to synthesize, in parallel, libraries of up to 96 compounds at a time, perform reaction work up, and crude purifications with minimal user input. There is no similar or related equipment at SFU, and a further delay in acquiring the automated synthesis platform would significantly impact our ability to translate expertise in chemical screening and synthesis into practical advances in medicine and materials.